Please Wait
Applying Filters...
menu
    • menu
    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Doravirine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck's Doravirine/Islatravir NDA Accepted by FDA
    Merck's Doravirine/Islatravir NDA Accepted by FDA

    10 Jul 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250710518672/en/U.S.-FDA-Accepts-New-Drug-Application-for-Mercks-DoravirineIslatravir-an-Investigational-Once-Daily-Oral-Two-Drug-Regimen-for-Treatment-of-Adults-with-Virologically-Suppressed-HIV-1-Infection

    BUSINESSWIRE
    10 Jul 2025
    Share Share
    Merck to Unveil Hiv Prevention, Treatment Data at IAS 2025
    Merck to Unveil Hiv Prevention, Treatment Data at IAS 2025

    09 Jul 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/diagnostic-center/merck-to-present-new-research-data-across-its-hiv-prevention-and-treatment-pipeline-at-ias-2025-17375

    INDPHARMAPOST
    09 Jul 2025
    Share Share
    Merck: Positive Phase 3 Data on Doravirine/Islatravir HIV Regimen
    Merck: Positive Phase 3 Data on Doravirine/Islatravir HIV Regimen

    12 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250312706063/en

    BUSINESSWIRE
    12 Mar 2025
    Share Share
    Merck's HIV combo treatment meets efficacy bar in Ph 3 trials
    Merck's HIV combo treatment meets efficacy bar in Ph 3 trials

    20 Dec 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/mercks-hiv-combo-treatment-meets-bar-viral-suppression-pair-phase-3-studies

    FIERCE BIOTECH
    20 Dec 2024
    Share Share
    Merck Opens Enrollment in PIII with Islatravir in Combination with Doravirine
    Merck Opens Enrollment in PIII with Islatravir in Combination with Doravirine

    22 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230222005448/en

    BUSINESSWIRE
    22 Feb 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Delstrigo (Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate)
    FDA Confirms Paragraph IV Patent Litigation for Delstrigo (Doravirine, Lamivudine and Tenofovir Disoproxil Fumarate)

    03 Oct 2022

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-delstrigo-doravirine-lamivudine-and-tenofovir-disoproxil-fumarate-27898.pdf

    FDA
    03 Oct 2022
    Share Share